Financial Performance - The company's operating revenue for Q1 2022 was ¥131,319,672.55, representing a 66.20% increase compared to ¥79,013,655.06 in the same period last year[4] - The net profit attributable to shareholders was -¥8,583,730.95, an improvement of 21.84% from -¥10,982,525.37 year-on-year[4] - The total operating costs for Q1 2022 were CNY 146,259,169.33, up 60.5% from CNY 91,171,975.04 in Q1 2021[26] - Net profit for Q1 2022 was a loss of CNY 8,583,730.95, an improvement from a loss of CNY 10,982,525.37 in Q1 2021, representing a reduction of 21.5%[27] - The company reported a basic and diluted earnings per share of -0.09, an improvement from -0.14 in the previous year[28] Cash Flow and Liquidity - The net cash flow from operating activities was -¥193,250,545.06, a decline of 39.15% compared to -¥138,881,683.81 in the previous year[4] - The total cash inflow from operating activities was CNY 129,245,059.33, slightly up from CNY 128,567,048.17 in the previous year[31] - The net cash flow from investment activities was -517,453,534.57 CNY, a significant decrease compared to 52,803.29 CNY in the previous period[32] - The net cash flow from financing activities was 826,578,481.17 CNY, a notable rise from 57,000,000.00 CNY in the previous period[32] - The ending balance of cash and cash equivalents was 305,091,543.28 CNY, significantly higher than 13,392,381.07 CNY at the end of the previous period[32] Assets and Liabilities - The total assets at the end of the reporting period reached ¥1,877,707,010.10, up 51.58% from ¥1,238,773,077.20 at the end of the previous year[4] - The total liabilities decreased to CNY 323,535,629.97 from CNY 616,494,385.62, a reduction of approximately 47.5%[23] - The company has a non-current asset total of CNY 113,686,299.76, up from CNY 98,469,386.21, representing a growth of about 15.5%[23] - Owner's equity increased significantly to CNY 1,532,980,475.02 from CNY 592,061,371.31, marking a growth of 158.5%[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,631[14] - The largest shareholder, Tan Pingtao, holds 44.23% of shares, totaling 46,708,990 shares[14] - The second largest shareholder, Shanghai Fosun Chuanghong Equity Investment Fund, holds 8.93% with 9,427,970 shares[14] - The company is actively managing its shareholder structure, with a focus on maintaining control among key stakeholders[15] - The company is committed to transparency regarding shareholder relationships and potential conflicts of interest[15] Research and Development - The company’s R&D expenses for Q1 2022 were ¥10,160,474.31, a 65.41% increase from ¥6,142,506.07 in the previous year[11] - Research and development expenses increased to CNY 10,160,474.31, up 65.5% from CNY 6,142,506.07 in the previous year[27] Market Strategy - The company plans to expand its market presence following its IPO, which was approved by the China Securities Regulatory Commission[19] - The company has invested in new technologies and product development, as indicated by the increase in intangible assets to CNY 33,891,330.54 from CNY 18,976,730.37, a growth of approximately 78.6%[23] Audit and Compliance - The company did not conduct an audit for the first quarter report[33]
华康医疗(301235) - 2022 Q1 - 季度财报